tirzepatide conversion to semaglutide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are Experiences switching from semaglutide to

Clinician oversight Cagrilintide is not approved for individual self-administration

Samples were incubated at room temperature for 1 h, vortexing intermittently, and then quenched by the addition of hydroxylamine (5 L of 5% w/v in HPLC water per sample) and incubated for 15 min at room temperature

This work was supported by a philanthropic gift from the McNair Medical Institute at the Robert and Janice McNair Foundation in Houston, TX

The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use

The results showed no statistically significant increase in thyroid cancer risk with GLP-1 receptor agonist treatment

These findings provided the closest available in vivo molecular signature for brain IR in depression and showed important sex differences in these pathways